SRC and prostate carcinoma: mir-99a and mir-99b inhibit proliferation of c-Src-transformed cells and prostate cancer cells by targeting mTOR [66, 67] and were identified as novel targets in some important biological process, such as the TGF-β-induced epithelial to mesenchymal transition [68].